XTL BIOPHARMACEUTICALS-ADR (XTLB) Stock Price, Forecast & Analysis

USA • Nasdaq • NASDAQ:XTLB • US98386D3070

1.06 USD
-0.01 (-0.93%)
At close: Feb 5, 2026
1.0503 USD
-0.01 (-0.92%)
After Hours: 2/5/2026, 6:04:59 PM

XTLB Key Statistics, Chart & Performance

Key Statistics
Market Cap10.03M
Revenue(TTM)N/A
Net Income(TTM)N/A
Shares9.46M
Float8.76M
52 Week High2.57
52 Week Low0.53
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)N/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPO2000-09-01
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
XTLB short term performance overview.The bars show the price performance of XTLB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 40 60

XTLB long term performance overview.The bars show the price performance of XTLB in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 -10 20 -20 -30

The current stock price of XTLB is 1.06 USD. In the past month the price increased by 60.58%. In the past year, price decreased by -30.26%.

XTL BIOPHARMACEUTICALS-ADR / XTLB Daily stock chart

XTLB Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to XTLB. When comparing the yearly performance of all stocks, XTLB is a bad performer in the overall market: 78.61% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

XTLB Financial Highlights


Industry RankSector Rank
PM (TTM) N/A
ROA N/A
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)N/A
Revenue 1Y (TTM)N/A

XTLB Forecast & Estimates


Analysts
Analysts0
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

XTLB Ownership

Ownership
Inst OwnersN/A
Ins Owners6.93%
Short Float %6.51%
Short Ratio0.67

XTLB Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC15.08383.716B
AMGN AMGEN INC16.32197.191B
GILD GILEAD SCIENCES INC16.72181.425B
VRTX VERTEX PHARMACEUTICALS INC22.54119.38B
REGN REGENERON PHARMACEUTICALS16.581.459B
ALNY ALNYLAM PHARMACEUTICALS INC46.2546.497B
INSM INSMED INC N/A32.511B
NTRA NATERA INC N/A28.376B
BIIB BIOGEN INC1227.206B
UTHR UNITED THERAPEUTICS CORP16.2520.78B

Related stock screener links

View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges

About XTLB

Company Profile

XTLB logo image XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The firm pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong a survival of patients for treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by kidneys. EPO stimulates erythropoiesis, production of red blood cells, by binding to its receptor on a surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.

Company Info

XTL BIOPHARMACEUTICALS-ADR

5 Badner St., P.O.Box 8241

Ramat Gan 4365603 IL

CEO: Shlomo Shalev

Employees: 33

XTLB Company Website

XTLB Investor Relations

Phone: 97299557080

XTL BIOPHARMACEUTICALS-ADR / XTLB FAQ

What does XTLB do?

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The firm pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong a survival of patients for treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by kidneys. EPO stimulates erythropoiesis, production of red blood cells, by binding to its receptor on a surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.


Can you provide the latest stock price for XTL BIOPHARMACEUTICALS-ADR?

The current stock price of XTLB is 1.06 USD. The price decreased by -0.93% in the last trading session.


Does XTLB stock pay dividends?

XTLB does not pay a dividend.


What is the ChartMill technical and fundamental rating of XTLB stock?

XTLB has a ChartMill Technical rating of 4 out of 10.You can find more details on the Technical Analysis and Fundamental Analysis tabs.


What sector and industry does XTL BIOPHARMACEUTICALS-ADR belong to?

XTL BIOPHARMACEUTICALS-ADR (XTLB) operates in the Health Care sector and the Biotechnology industry.


What is the Short Interest ratio of XTL BIOPHARMACEUTICALS-ADR (XTLB) stock?

The outstanding short interest for XTL BIOPHARMACEUTICALS-ADR (XTLB) is 6.51% of its float.